Orangebiomed
Seoul
About Orangebiomed
Orange Biomed is developing "OBM rapid A1c", the world-first reusable and portable HbA1c device for better diabetes management. Orange Biomed's advanced microfluidic technology brings a lab-accurate blood test to patient's home, providing A1c test for anyone, anytime, and anywhere. With only a drop of blood sample, patients can easily monitor their A1c level at home at affordable price, saving time traveling back and forth from doctor's office.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $7.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2025)
- Website: orangebiomed.com
- Phone: [email protected]
Industries & Categories
Diabetes, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/orangebiomed-130266 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.